Some recent studies revealed that PD-1/PD-L1 inhibition may downregulate PI3K/AKT and MAPK/ERK pathway-mediated MDR1/P-gp expression in breast cancer cells, suggesting that this effect probably contributes to increased chemotherapy efficacy in breast cancer patients [47–49]. This evidence concerns the gene AKT1 and breast carcinoma.